Sort   by:  
 Page size 
MetabolomicsLimosilactobacillus reuteri in Promoting Growth Performance and Regulating Lipid Metabolism in Zuili Black Pigs

Abstract

Background

The gut microbiota is a key regulator of host lipid metabolism. In indigenous pigs, variation in growth performance and intramuscular fat (IMF) deposition has been linked to microbiota-host interactions, yet the specific taxa and metabolites that govern host lipid ...

2025-09-20 | MTBLS13017 | MetaboLights
MetabolomicsLimosilactobacillus reuteri with indole-3-lactic acid-producing capacity protects against atherosclerosis by fortifying the gut-vascular barrier

Introduction: The gut microbiota and its metabolites are implicated in atherosclerosis, but the specific effector molecules and their pathophysiological significance remain unclear.

Objectives: This study aimed to identify key atheroprotective microbial metabolites and to elucidate the mech...

2026-01-31 | MTBLS13620 | MetaboLights
MetabolomicsIntegrated Multi-omics Elucidation of the Uric Acid Degradation Pathway in Limosilactobacillus fermentum M5e

Hyperuricemia is a growing global health concern associated with gout, renal diseases, and cardiovascular disorders. Current pharmacotherapies are often limited by side effects, underscoring the need for alternative strategies. In this study, we isolated Limosilactobacillus fermentum M5...

2026-01-26 | MTBLS13223 | MetaboLights
MetabolomicsLimosilactobacillus fermentum-derived 4-guanidinobutyric acid promotes intestinal urate excretion via the HNF4α-ABCG2 axis to alleviate hyperuricemia

Hyperuricemia is a prevalent metabolic illness and an established risk factor for gout and chronic renal disease. Present urate-lowering medications are often limited by side effects, highlighting the necessity for innovative strategies. The gut microbiota has a role in urate homeostasis; however...

2026-01-26 | MTBLS13637 | MetaboLights
ProteomicsProteomic analysis of Limosilactobacillus reuteri DSM 17938
The aim of this work was to assess the antibiofilm activity of Cell Free Supernatant (CFS) produced by Limosilactobacillus reuteri DSM 17938 versus biofilm-producer bacterial species of clinical relevance.
ORGANISM(S): Escherichia coli 
2025-06-09 | PXD035326 | Pride
Extracellular membrane vesicles Postbiotics Lactobacillus reuteri Cytotoxicity  metabolomics Probiotics Limosilactobacillus reuteri Antibiofilm activity Cell free supernatant 
ProteomicsThe use of omics technologies in creating LBP and postbiotics based on the Limosilactobacillus fermentum U-21
In recent years, there has been an increasing tendency to create drugs of various types based on certain commensal bacteria of the human microbiota and their ingredients. This primarily concerns live biotherapeutics (LBPs) and postbiotics. The creation of such drugs, which can be called pharmacobiot...
ORGANISM(S): Limosilactobacillus fermentum 
2024-06-04 | PXD050857 | Pride
Pharmabiotics Metabolome Omics technologies Limosilactobacillus fermentum u-21 Proteome Postbiotics 
GenomicsLimosilactobacillus reuteri
Limosilactobacillus reuteri Genome sequencing
PRJNA994435 | ENA
GenomicsLimosilactobacillus fermentum
Limosilactobacillus fermentum Genome sequencing
PRJNA1118680 | ENA
GenomicsLimosilactobacillus reuteri
Limosilactobacillus reuteri Genome sequencing
PRJNA1212859 | ENA
GenomicsLimosilactobacillus reuteri isolate:QS01
Limosilactobacillus reuteri isolate:QS01 Genome sequencing
PRJNA888459 | ENA
Sort   by:  
 Page size